Bioequivalence of domperidone tablets in healthy male volunteers
Li Ling, Na Gao, Juan Gu, Yan Jin, Yang Guoping, Dongsheng Ouyang
Abstract
Li Ling, Na Gao, Juan Gu, Yan Jin, Yang Guoping, Dongsheng Ouyang
Abstract
AIM:To evaluate the pharmacokinetics and bioequivalence of domperidone tablets in healthy volunteers.METHODS: A single dose(20 mg test or reference formation) was given to 18 healthy male volunteers according to an open randomized crossover design.The concentration of domperidone in plasma was determined by LC-MS.The pharmacokinetics parameters were calculated and the bioavailability and bioequivalence of two formulations were evaluated by DAS Ver 2.0.RESULTS: The main pharmacokinetic parameters of domperidone tablets were as follows: Cmax were(36±8) and(38±9) μg/L;tmax were(0.6±0.2) and(0.7±0.3) h;t1/2 were(10±8) and(9±3) h;AUC0-24 were(138±34) and(144±31) μg·L-1·h;AUC0-∞ were(168±68) and(166±37) μg·L-1·h.As assessed in accordance with AUC0-24,the relative bioavailability of two formulations was(97±20)%.CONCLUSION: The domperidone formulations are bioequivalent.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
AIM:To evaluate the pharmacokinetics and bioequivalence of domperidone tablets in healthy volunteers.METHODS: A single dose(20 mg test or reference formation) was given to 18 healthy male volunteers according to an open randomized crossover design.The concentration of domperidone in plasma was determined by LC-MS.The pharmacokinetics parameters were calculated and the bioavailability and bioequivalence of two formulations were evaluated by DAS Ver 2.0.RESULTS: The main pharmacokinetic parameters of domperidone tablets were as follows: Cmax were(36±8) and(38±9) μg/L;tmax were(0.6±0.2) and(0.7±0.3) h;t1/2 were(10±8) and(9±3) h;AUC0-24 were(138±34) and(144±31) μg·L-1·h;AUC0-∞ were(168±68) and(166±37) μg·L-1·h.As assessed in accordance with AUC0-24,the relative bioavailability of two formulations was(97±20)%.CONCLUSION: The domperidone formulations are bioequivalent.
Key concepts: Bioequivalence, Domperidone, Bioavailability, Pharmacokinetics, Cmax, Crossover study, Pharmacology, Medicine